Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks-Reference-Cited by-同舟云学术

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Published:2006 Issue:9 Volume:54 Page:2793-2806
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Cohen Stanley B.,Emery Paul,Greenwald Maria W.,Dougados Maxime,Furie Richard A.,Genovese Mark C.,Keystone Edward C.,Loveless James E.,Burmester Gerd-Rüdiger,Cravets Matthew W.,Hessey Eva W.,Shaw Timothy,Totoritis Mark C.,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.22025/fullpdf

Reference41 articles.

1. Epidemiology of rheumatic diseases

2. Rheumatoid Arthritis—A Molecular Understanding

3. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

4. FACTORS PREDICTING DEATH, SURVIVAL AND FUNCTIONAL OUTCOME IN A PROSPECTIVE STUDY OF EARLY RHEUMATOID DISEASE OVER FIFTEEN YEARS

5. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

Cited by 1368 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis;Nature Reviews Rheumatology;2024-09-06

2. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy;Joint Bone Spine;2024-09

3. Comparing Immunogenicity and Safety following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in patients with Rheumatoid Arthritis: A Randomized, Double- blind, Phase 3 Study;2024-08-11

4. Newer Immunosuppressants for Rheumatologic Disease;Rheumatic Disease Clinics of North America;2024-08

5. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions;Seminars in Arthritis and Rheumatism;2024-08